S&P Futures
3,919.75 +22.00 (+0.56%) Dow Futures
31,331.00 +129.00 (+0.41%) Nasdaq Futures
11,981.75 +103.50 (+0.87%) Russell 2000 Futures
1,788.90 +14.00 (+0.79%) Crude Oil
111.65 -0.56 (-0.50%) Gold
1,847.00 +5.80 (+0.32%)
Northwest Biotherapeutics, Inc. (NWBO)
Chart Events
Performance Outlook
| Previous Close | 0.6929 |
| Open | 0.7090 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.6630 - 0.7199 |
| 52 Week Range | 0.3900 - 2.0500 |
| Volume | |
| Avg. Volume | 4,118,050 |
| Market Cap | 684.052M |
| Beta (5Y Monthly) | 0.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0630 |
| Earnings Date | Aug 08, 2020 - Aug 12, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NWBO
Related Research
- NORTHWEST BIOTHERAPEUTICS INCAnalyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.RatingFair ValueEconomic Moat2 days agoArgus Research
- PR Newswire
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made today at 11:10 a.m., at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences. The presentation will be made by Dr. Paul Mulholland of University College Hospital.
- PR Newswire
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made on May 10, 2022 at 11:10 a.m., by Dr. Linda Liau at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.
- PR Newswire
Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a compassionate use patient at its recently licensed production facility in Sawston, UK.
